Want to join the conversation?
As a result of the spin-off of Baxalta on July 1, 2015, $BAX is re-evaluating its assertions relating to prior earnings outside the U.S. that were previously deemed indefinitely reinvested. $BAX expects to amend certain assertions and, as a consequence, may record a significant tax charge in 3Q15.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.